Hyper-Eosinophilic Syndrome with Myocarditis after Inactivated SARSCoV-2 Vaccination-A Case Study

Introduction COVID-19 vaccine-induced serious adverse reactions are rare. Hyper-eosinophilia syndrome with myocarditis has not been reported earlier following BBV152 vaccine administration. Case Presentation A young man without any co-morbidities presented with persistent periorbital swelling along with itchy swelling over fingers, resting tachycardia, and exertional breathlessness following the first dose of an inactivated SARS-CoV-2 vaccine (BBV152, COVAXIN). On investigation, the patient had elevated blood eosinophils (maximum 21.5% with an absolute eosinophil count of 2767/mm(3)) and myocarditis (Lake Louise Criteria). He was successfully treated with steroids and supportive treatment. Conclusion This is the first reported case of hyper-eosinophilia syndrome after COVAXIN administration. Prior history of the allergic disease may be a predisposing factor in this case. Hyper-eosinophilia can present with variable symptoms. In the current case, myocarditis was present with persistent resting tachycardia and dyspnea. Steroid and antiallergic drugs may be successful for the treatment of vaccine-induced hyper-eosinophilia with myocarditis. Increased vigilance is needed for such adverse events.

Automated summary

A young man presented with periorbital swelling, finger swelling, tachycardia, and breathlessness after receiving the COVAXIN vaccine. He was found to have elevated blood eosinophils and myocarditis. Treatment with steroids and supportive care resulted in successful recovery. This is the first reported case of hyper-eosinophilia syndrome after COVAXIN administration, and vigilance is necessary for such adverse events.